Flash Finance

Biocon LimitedBIOCONCorporate

Healthcare Biotechnology Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹349.20
MCap ₹56,860 Cr · P/E n/m
Biocon Limited — Stock analysis & AI research Biocon Limited — Multibagger AI analysis Biocon Limited — Seasonality — best & worst months Biocon Limited — Technical indicators & charts Biocon Limited — Technical setup — score, trend, support & resistance Biocon Limited — Double Top pattern broken down ↓ Biocon Limited — Live exchange announcements
📋 Mid Cap Stocks List 📈 Death Cross Stocks📈 RSI Oversold Stocks📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹624 Cr
Sales · Jun 2026
+16.3% YoY
₹61 Cr
Operating Profit · Jun 2026
+195.1% YoY
9.7%
OPM % · Jun 2026
+155.3% YoY
₹52 Cr
Net Profit · Jun 2026
+728.9% YoY
₹0.32
EPS · Jun 2026
+557.1% YoY

📝 Biocon Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Biocon Limited reported revenue of ₹624 crore for the quarter ended June 2026 (Q1 FY27), up 16.3% from ₹537 crore in the same quarter last year, and up 3.2% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹52 crore from a net loss of ₹8 crore a year earlier. Earnings per share (EPS) came in at ₹0.32.

Operating profit stood at ₹61 crore — an operating margin (OPM) of 9.7%, compared with 3.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Biocon Limited posted revenue of ₹2,347 crore, a growth of 4.6% over FY25, with a net profit of ₹37 crore (down 93.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,434 crore with a net profit of ₹98 crore.

Valuation snapshot

At the current price of ₹349.20, BIOCON has a market capitalisation of ₹56,860 crore and a P/E that is not meaningful, because trailing profit is close to zero.

Within the Biotechnology industry, it is the largest of the 8 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 44.68%, foreign institutional investors (FIIs) 8.16%, domestic institutional investors (DIIs) 23.37%, public shareholders 23.74% of Biocon Limited.

Promoter holding slipped from 44.91% to 44.68% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹56,860 Cr
Current Price ?
₹349.2
P/E ?
n/m
Industry P/E ?
106.70
P/B ?
2.10
P/S ?
23.36
P/FCF ?
-121.24
Enterprise Value ?
₹58,013 Cr
EV/EBITDA ?
218.09
PEG ?
n/m
Earnings Yield ?
0.2%
Dividend Yield ?
0.14%
Profitability & Returns
Sales (TTM) ?
₹2,434 Cr
OPM ?
10.9%
Profit after tax (TTM) ?
₹98 Cr
EPS (TTM) ?
₹0.60
ROCE ?
2.0%
ROE ?
0.4%
ROA ?
0.3%
Growth
Sales — latest qtr ?
₹624 Cr
PAT — latest qtr ?
₹52 Cr
YoY qtr sales growth ?
16.3%
YoY qtr profit growth ?
728.9%
Sales growth (3y) ?
6%
Sales growth (5y) ?
3%
Profit growth (3y) ?
171%
Profit growth (5y) ?
-3%
Financial Health
Debt ?
₹1,153 Cr
Debt to Equity ?
0.04
Interest Coverage ?
0.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
44.68%
Change in promoter holding ?
-9.77%
Pledged percentage ?
N/A
Market
Return 3 months ?
-20.1%
Return 6 months ?
-2.5%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 555507513519563533511525563644537583621605624 +16.3% +3.2%
Operating Profit 37-4472677152453831622153737961 +195.1% -23.0%
Other Income 6064566448394274646361134753165 +5.7% +109.0%
Interest 21484855564055606557566721717 -69.2% +1.8%
Depreciation 292930313130303034333334343638 +15.3% +6.7%
Profit Before Tax 461,7965046332212160435-886-845770 +1019.7% +22.6%
Net Profit 351,811473524141358421-871-765152 +728.9% +2.4%
EPS 0.2915.170.390.290.200.120.010.034.880.18-0.070.55-0.570.310.32 +557.1% +3.2%
OPM % 6.7% -8.7% 14.0% 12.9% 12.7% 9.8% 8.8% 7.2% 5.6% 9.6% 3.8% 9.1% 11.8% 13.1% 9.7% +155.3% -26.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,243 Cr ₹2,347 Cr ₹2,434 Cr +4.6%
Operating Profit ₹176 Cr ₹226 Cr ₹266 Cr +28.4%
OPM % 7.84% 9.62% 10.93% +22.7%
NPM % 27.17% 1.59% 4.01% -94.1%
Other Income ₹242 Cr ₹301 Cr ₹304 Cr +24.2%
Depreciation ₹128 Cr ₹137 Cr ₹142 Cr +7.3%
Interest ₹237 Cr ₹143 Cr ₹104 Cr -39.8%
EBIT ₹48 Cr ₹89 Cr ₹124 Cr +84.8%
PBT ₹661 Cr ₹51 Cr ₹128 Cr -92.3%
Tax ₹52 Cr ₹7 Cr ₹24 Cr -85.7%
Net Profit ₹609 Cr ₹37 Cr ₹98 Cr -93.9%
EPS ₹5.10 ₹0.22 ₹0.61 -95.7%
Material Cost ₹1,085 Cr ₹942 Cr ₹901 Cr -13.3%
Employee Cost ₹501 Cr ₹374 Cr ₹381 Cr -25.5%
Extraordinary Items ₹608 Cr ₹-196 Cr ₹-196 Cr -132.3%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 600600600810 +35.0%
Reserves 10,31610,31210,92426,269 +140.5%
Borrowings 1,3012,0432,8761,153 -59.9%
Other Liabilities 8138131,2211,038 -15.0%
Total Liabilities 13,03013,76815,62129,271 +87.4%
Fixed Assets 9619581,1141,399 +25.6%
CWIP 344560701523 -25.4%
Investments 9,2719,31811,38324,978 +119.4%
Other Assets 2,4542,9322,4242,371 -2.2%
Total Assets 13,03013,76815,62129,271 +87.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 219-123624-180 -128.8%
Cash from Investing Activity -1,173-295-992-6,582 -563.5%
Cash from Financing Activity 1,0393444956,602 +1233.7%
Net Cash Flow 86-74127-160 -226.0%
Free Cash Flow -45-429302-469 -255.3%
CFO/OP 1,103%-36%376%-70% -118.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 121180135156 +15.6%
Inventory Days 208260296299 +1.0%
Days Payable 169175288201 -30.2%
Cash Conversion Cycle 159265143254 +77.6%
Working Capital Days 1512443036 +20.0%
ROCE % 2%3%2%2% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 54.45%54.45%54.45%44.91%44.68% -0.5%
FIIs 6.04%6.61%7.39%7.52%8.16% +8.5%
DIIs 22.83%22.06%21.67%24.01%23.37% -2.7%
Government 0.00%0.03%0.03%0.05%— —
Public 16.51%16.70%16.34%23.40%23.74% +1.5%
Others 0.18%0.14%0.12%0.09%— —
No. of Shareholders 4,28,1314,13,1913,94,2793,86,5933,92,509 +1.5%

⚖️ Peer comparison

Industry: Biotechnology · 8 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 BIOCON Biocon ₹390.65 63,609 147.4 17,322 417 20.4% 2.4% 10.9% -74.2% 10.0% 53.4%
2 ANTHEM ANTHEM BIOSCIENCES ₹874.85 49,142 85.4 2,002 576 39.6% 28.8% — — -22.6% -11.7%
3 ONESOURCE ONESOURCE SPECL ₹1,592.00 18,256 — 1,544 -49 21.9% -3.2% -1.6% -185.0% 37.3% 0.7%
4 CONCORDBIO Concord Biotech ₹1,510.00 15,797 57.6 1,109 273 34.9% 24.6% -12.1% -30.4% 26.2% 31.0%
5 514336 CCME Global ₹15.10 150 — 0 -1 -2079.0% -2135.5% -98.9% -120.3% — -120.2%
6 511509 Vivo Bio ₹37.69 37 — 55 -3 37.0% -5.2% 14.3% -123.4% 14.1% -86.0%
7 539470 Shree Ganesh ₹1.20 18 — 5 -0 -35.3% -7.8% -78.4% 34.2% 3.6% -273.7%
8 539206 Genomic Valley ₹52.00 9 n/m 0 0 11.7% 6.7% -68.2% -94.4% -57.8% -26.9%
❓ Frequently asked questions
What was Biocon Limited's revenue in Q1 FY27?
Biocon Limited reported revenue of ₹624 crore for the quarter ended June 2026 (Q1 FY27), up 16.3% from ₹537 crore in the same quarter last year, and up 3.2% sequentially over the March 2026 quarter.
What was Biocon Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹52 crore from a net loss of ₹8 crore a year earlier. Earnings per share (EPS) came in at ₹0.32.
What is BIOCON's market capitalisation and P/E ratio?
At the current price of ₹349.20, BIOCON has a market capitalisation of ₹56,860 crore and a P/E that is not meaningful, because trailing profit is close to zero.
Who owns Biocon Limited? (shareholding pattern)
As of Jun 2026, promoters held 44.68%, foreign institutional investors (FIIs) 8.16%, domestic institutional investors (DIIs) 23.37%, public shareholders 23.74% of Biocon Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI